Cargando…

Screening for MicroRNA combination with engineered exosomes as a new tool against osteosarcoma in elderly patients

The most common primary malignant bone sarcoma is Osteogenic sarcoma (OS) which has a bimodal age distribution. Unfortunately, the treatment of OS was less effective for elderly patients than for younger ones. The study aimed to explore a new microRNA (miRNA) which can bind to combining engineered e...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Jiyu, Zhao, Zitong, Wang, Yanhong, Yu, Tao, Wan, Daqian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760984/
https://www.ncbi.nlm.nih.gov/pubmed/36545680
http://dx.doi.org/10.3389/fbioe.2022.1052252
_version_ 1784852606084972544
author Han, Jiyu
Zhao, Zitong
Wang, Yanhong
Yu, Tao
Wan, Daqian
author_facet Han, Jiyu
Zhao, Zitong
Wang, Yanhong
Yu, Tao
Wan, Daqian
author_sort Han, Jiyu
collection PubMed
description The most common primary malignant bone sarcoma is Osteogenic sarcoma (OS) which has a bimodal age distribution. Unfortunately, the treatment of OS was less effective for elderly patients than for younger ones. The study aimed to explore a new microRNA (miRNA) which can bind to combining engineered exosomes for treatment of older OS patients. Based on GSE65071 and miRNet 2.0, two up-regulated miRNAs (miR-328, miR-107) and seven down-regulated miRNAs (miR-133b, miR-206, miR-1-3p, miR-133a, miR-449a, miR-181daysay, miR-134) were selected. Next, we used FunRich software to predict the up-stream transcription factors (TFs) of differentially expressed miRNAs (DE-miRNAs). By comparing target genes predicted from DE-miRNAs with differentially expressed genes, we identified 12 down-regulated and 310 up-regulated mRNAs. For KEGG analysis, the most enriched KEGG pathway was Cell cycle, Spliceosome, and Protein digestion and absorption. By using protein-protein interactions network, topological analysis algorithm and GEPIA database, miR-449a /CCNB1 axis was identified. Experiments in vitro were conducted to confirm the results too. MiRNA-449a is down-regulated in osteosarcoma and suppresses cell proliferation by targeting CCNB1. Our findings not only reveal a novel mechanism of miR-449a /CCNB1 in OS but also had laid the groundwork for further investigation and analysis in the field of exosome engineering.
format Online
Article
Text
id pubmed-9760984
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97609842022-12-20 Screening for MicroRNA combination with engineered exosomes as a new tool against osteosarcoma in elderly patients Han, Jiyu Zhao, Zitong Wang, Yanhong Yu, Tao Wan, Daqian Front Bioeng Biotechnol Bioengineering and Biotechnology The most common primary malignant bone sarcoma is Osteogenic sarcoma (OS) which has a bimodal age distribution. Unfortunately, the treatment of OS was less effective for elderly patients than for younger ones. The study aimed to explore a new microRNA (miRNA) which can bind to combining engineered exosomes for treatment of older OS patients. Based on GSE65071 and miRNet 2.0, two up-regulated miRNAs (miR-328, miR-107) and seven down-regulated miRNAs (miR-133b, miR-206, miR-1-3p, miR-133a, miR-449a, miR-181daysay, miR-134) were selected. Next, we used FunRich software to predict the up-stream transcription factors (TFs) of differentially expressed miRNAs (DE-miRNAs). By comparing target genes predicted from DE-miRNAs with differentially expressed genes, we identified 12 down-regulated and 310 up-regulated mRNAs. For KEGG analysis, the most enriched KEGG pathway was Cell cycle, Spliceosome, and Protein digestion and absorption. By using protein-protein interactions network, topological analysis algorithm and GEPIA database, miR-449a /CCNB1 axis was identified. Experiments in vitro were conducted to confirm the results too. MiRNA-449a is down-regulated in osteosarcoma and suppresses cell proliferation by targeting CCNB1. Our findings not only reveal a novel mechanism of miR-449a /CCNB1 in OS but also had laid the groundwork for further investigation and analysis in the field of exosome engineering. Frontiers Media S.A. 2022-12-05 /pmc/articles/PMC9760984/ /pubmed/36545680 http://dx.doi.org/10.3389/fbioe.2022.1052252 Text en Copyright © 2022 Han, Zhao, Wang, Yu and Wan. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Bioengineering and Biotechnology
Han, Jiyu
Zhao, Zitong
Wang, Yanhong
Yu, Tao
Wan, Daqian
Screening for MicroRNA combination with engineered exosomes as a new tool against osteosarcoma in elderly patients
title Screening for MicroRNA combination with engineered exosomes as a new tool against osteosarcoma in elderly patients
title_full Screening for MicroRNA combination with engineered exosomes as a new tool against osteosarcoma in elderly patients
title_fullStr Screening for MicroRNA combination with engineered exosomes as a new tool against osteosarcoma in elderly patients
title_full_unstemmed Screening for MicroRNA combination with engineered exosomes as a new tool against osteosarcoma in elderly patients
title_short Screening for MicroRNA combination with engineered exosomes as a new tool against osteosarcoma in elderly patients
title_sort screening for microrna combination with engineered exosomes as a new tool against osteosarcoma in elderly patients
topic Bioengineering and Biotechnology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760984/
https://www.ncbi.nlm.nih.gov/pubmed/36545680
http://dx.doi.org/10.3389/fbioe.2022.1052252
work_keys_str_mv AT hanjiyu screeningformicrornacombinationwithengineeredexosomesasanewtoolagainstosteosarcomainelderlypatients
AT zhaozitong screeningformicrornacombinationwithengineeredexosomesasanewtoolagainstosteosarcomainelderlypatients
AT wangyanhong screeningformicrornacombinationwithengineeredexosomesasanewtoolagainstosteosarcomainelderlypatients
AT yutao screeningformicrornacombinationwithengineeredexosomesasanewtoolagainstosteosarcomainelderlypatients
AT wandaqian screeningformicrornacombinationwithengineeredexosomesasanewtoolagainstosteosarcomainelderlypatients